The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis

Laboratory Investigation

Volumn 94, Issue 8, 2014, Pages 839-850

  Zhang, Lei ^a   Hao, Jian Bing ^a   Ren, Lian Sheng ^a   Ding, Jiu Li ^b   Hao, Li Rong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b Hospital of Heilongjiang Province   (China)

Author keywords

aldosterone; c Jun; MCP 1; peritoneal fibrosis; TGF 1

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; CD4 ANTIGEN; CILAZAPRIL; COLLAGEN; FIBRONECTIN; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C JUN; SPIRONOLACTONE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIALYSATE LEVEL; DOWN REGULATION; ENZYME INACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL PERITONITIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MORNING DOSAGE; NONHUMAN; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CILAZAPRIL; DIALYSIS SOLUTIONS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; LYMPHOCYTES; MACROPHAGES; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEAL FIBROSIS; PERITONEUM; PERITONITIS; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84905190078     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.69     Document Type: Article

References (42)

1. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
2. David F, David K. Macrophage cell therapy in renal disease. Semin Nephrol 2010;30:345-353.
3. Vernon MA, Mylonas KJ, Hughes J. Macrophages and renal fibrosis. Semin Nephrol 2010;30:302-317.
4. Margetts PJ, Oh KH, Kolb M. Transforming growth factor-beta: importance in long-term peritoneal membrane changes. Perit Dial Int 2005;25(suppl 3):S15-S17.
5. Lai KN, Lai KB, Lam CW, et al. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000;35:644-652.
6. Loureiro J, Aguilera A, Selgas R, et al. Blocking TGF-b1 protects the peritoneal membrane from dialysate-induced damage. Am Soc Nephrol 2011;22:1682-1695.
7. Engel ME, McDonnell MA, Law BK, et al. Interdependent Smad and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 1999;274:37413-37420.
8. Hocevar BA, Prunier C, Howe PH. Disabled-2 (dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J Biol Chem 2005;280:25920-25927.
9. Alcorn JF, Guala AS, van der Velden J, et al. Jun n-terminal kinase 1 regulates epithelialto-mesenchymal transition induced by TGF-beta1. J Cell Sci 2008;121:1036-1045.
10. Alcorn JF, van der Velden J, Brown AL, et al. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 2009;40:422-432.
11. Nakajima T, Yamada T, Setoguchi M. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;19:102-107.
12. Naftilan AJ, Pratt MJ, Owens GK. Induction of platelet-derived growth factor A chain and c-myc gene expression by Angiotensin II in cultured rat muscle cells. J Clin Invest 1989;83:1419-1424.
13. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor-b1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-461.
14. Lemarié CA, Simeone SM, Nikonova A, et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 2009;105:852-859.
15. Han JS, Choi BS, Yang CW, et al. Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci 2009;24:S195-S203.
16. Nie J, Dou X, Hao W, et al. Smad7 gene transfer inhibits peritoneal fibrosis. Kidney Int 2007;72:1336-1344.
17. Sach M, Loetscher P, Burger JA, et al. MCP-1 levels are elevated in peritonitis fluid from CAPD patients due to secretion by peritoneal macrophages. Adv Perit Dial 1995;11:19-23.
18. Sach M, Bauermeister K, Burger JA, et al. Inverse MCP-1/IL-8 ratio in effluents of CAPD patients with peritonitis and in isolated cultured human peritoneal macrophages. Nephrol Dial Transplant 1997;12:3 15-320.
19. Nakanishi I, Moutabarrik A, Okada N, et al. Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant 1994;9: 1435-1442.
20. Tekstra J, Visser CE, Tuk CW, et al. Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. J Am Soc Nephrol 1996;7:2379-2384.
21. Robson LR, McLouglin MR, Witowski J, et al. Differential regulation of chemokine production in human peritoneal mesothelial cells: INF-g controls neutrophil migration across the mesothelium in vitro and in vivo. J Immunol 2001;167:1028-1038.
22. Fieren MW. The local inflammatory responses to infection of the peritoneal cavity in humans: their regulation by cytokines, macrophages, and other leukocytes. Mediators Inflamm 2012;2012:976241.
23. Bellón T, Mart́inez V, Lucendo B, et al. Alternative activation of macrophages in human peritoneum: implications for peritoneal fibrosis. Nephrol Dial Transplant 2011;9:2995-3005.
24. Hu W, Jiang Z, Zhang Y, et al. Characterization of infiltrating macrophages in high glucose-induced peritoneal fibrosis in rats. Mol Med Rep 2012;1:93-99.
25. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007;19:142-149.
26. Flanc RS, Ma FY, Tesch GH, et al. A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int 2007;72: 698-708.
27. Francescato HD, Costa RS, Junior FB, et al. Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol Dial Transplant 2007;22: 2138-2148.
28. De Borst MH, Prakash J, Melenhorst WB, et al. Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. J Pathol 2007;213:219-228.
29. Mori S, Matsuzaki K, Yoshida K, et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 2004;23:7416-7429.
30. Verrecchia F, Tacheau C, Wagner EF, et al. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven Smad3/4-specific gene expression. J Biol Chem 2003;278:1585-1593.
31. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005;46:1227-1235.
32. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009;53:286-290.
33. Nagase M. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol 2010;14:303-314.
34. Bienvenu LA, Morgan J, Rickard AJ, et al. Macrophage mineralo-corticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology 2012;153:3416-3425.
35. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-820.
36. Zhou G, Kandala JC, Tyagi SC, et al. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 1996;154:171-178.
37. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005;45:773-779.
38. Miric G, Dallemagne C, Endre Z, et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-694.
39. Ha H, Lee HB. Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 2000;20(Suppl 2):S15-S18.
40. Eesoy R, Celik A, Yilmaz O, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007;27:424-431.
41. Terada Y, Kobayashi T, Kuwana H, et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, Cyclin D1, and CyclinA. J Am Soc Nephrol 2005;16:2296-2305.
42. Han J-S, Choi B-S, Yang C-W, et al. Aldosterone-induced TGF-b1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci 2009; 24(Suppl I):S195-S203.